Tuesday 12 June 2012

Summit Corporation PLC: Summit achieves SMT C1100 Phase 1 dosing milestone that triggers milestone payment

Summit Corporation PLC: Summit achieves SMT C1100 Phase 1 dosing milestone that triggers milestone payment: "SUMMIT ACHIEVES SMT C1100 PHASE 1 DOSING MILESTONE THAT TRIGGERS MILESTONE PAYMENT
* Trial moves to Multiple Dose stage
* Summit to Participate in Upcoming Industry Events
Summit (AIM: SUMM), a UK drug discovery company, today announced that it has successfully passed a milestone in the Phase 1 trial of SMT C1100 for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy ('DMD'), which triggered the final payment from a $1.5 million funding agreement with US-based DMD organisations."

'via Blog this'

No comments:

Post a Comment